Rothschild & CO Asset Management Us Inc. Revance Therapeutics, Inc. Transaction History

Rothschild & CO Asset Management Us Inc.

$6.56 Billion
Q4 2022

A detailed history of Rothschild & CO Asset Management Us Inc. transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Rothschild & CO Asset Management Us Inc. holds 369,648 shares of RVNC stock, worth $949,995. This represents 0.1% of its overall portfolio holdings.

Number of Shares

369,648

Previous 214,935 71.98%

Holding current value

$949,995

Previous $5.8 Million 17.58%

% of portfolio

0.1%

Previous 0.1%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $2.83 Million - $4.74 Million	154,713 Added 71.98%	369,648 $6.82 Million
Q3 2022 Nov 07, 2022	SELL	$14.33 - $28.47 $21,996 - $43,701	-1,535 Reduced 0.71%	214,935 $5.8 Million
Q2 2022 Aug 09, 2022	SELL	$11.52 - $20.4 $68,405 - $121,135	-5,938 Reduced 2.67%	216,470 $2.99 Million
Q1 2022 May 13, 2022	SELL	$12.36 - $20.31 $824,609 - $1.36 Million	-66,716 Reduced 23.08%	222,408 $4.34 Million
Q4 2021 Feb 11, 2022	SELL	$12.46 - $27.87 $188,744 - $422,174	-15,148 Reduced 4.98%	289,124 $4.72 Million
Q3 2021 Nov 09, 2021	SELL	$25.78 - $33.21 $1.05 Million - $1.35 Million	-40,759 Reduced 11.81%	304,272 $8.48 Million
Q2 2021 Aug 16, 2021	SELL	$26.8 - $31.84 $1.04 Million - $1.24 Million	-38,797 Reduced 10.11%	345,031 $10.2 Million
Q1 2021 May 14, 2021	SELL	$24.03 - $29.97 $1.11 Million - $1.38 Million	-46,008 Reduced 10.7%	383,828 $10.7 Million
Q4 2020 Feb 08, 2021	SELL	$23.41 - $28.34 $198,633 - $240,464	-8,485 Reduced 1.94%	429,836 $12.2 Million
Q3 2020 Nov 09, 2020	SELL	$23.23 - $34.3 $1.05 Million - $1.55 Million	-45,255 Reduced 9.36%	438,321 $11 Million
Q2 2020 Aug 10, 2020	BUY	$12.6 - $26.55 $40,433 - $85,198	3,209 Added 0.67%	483,576 $11.8 Million
Q1 2020 May 14, 2020	SELL	$12.46 - $27.81 $989,286 - $2.21 Million	-79,397 Reduced 14.18%	480,367 $7.11 Million
Q4 2019 Feb 12, 2020	BUY	$11.66 - $20.15 $6.12 Million - $10.6 Million	524,707 Added 1496.73%	559,764 $9.09 Million
Q3 2019 Nov 08, 2019	BUY	$10.22 - $14.5 $78,039 - $110,722	7,636 Added 27.85%	35,057 $456,000
Q2 2019 Jul 25, 2019	SELL	$10.67 - $15.49 $3,104 - $4,507	-291 Reduced 1.05%	27,421 $356,000
Q1 2019 May 08, 2019	SELL	$15.4 - $20.39 $334,626 - $443,054	-21,729 Reduced 43.95%	27,712 $437,000
Q4 2018 Feb 05, 2019	BUY	$18.06 - $24.96 $10,655 - $14,726	590 Added 1.21%	49,441 $995,000
Q3 2018 Nov 13, 2018	BUY	$23.55 - $30.1 $171,891 - $219,699	7,299 Added 17.57%	48,851 $1.21 Million
Q2 2018 Aug 07, 2018	SELL	$27.45 - $33.35 $80,318 - $97,582	-2,926 Reduced 6.58%	41,552 $1.14 Million
Q1 2018 May 08, 2018	SELL	$29.15 - $37.4 $140,590 - $180,380	-4,823 Reduced 9.78%	44,478 $1.37 Million
Q4 2017 Feb 12, 2018	SELL	$24.55 - $36.3 $91,006 - $134,564	-3,707 Reduced 6.99%	49,301 $1.76 Million
Q3 2017 Nov 08, 2017	BUY	$22.55 - $28.1 $1.2 Million - $1.49 Million	53,008	53,008 $1.46 Million

Others Institutions Holding RVNC

# of Institutions

Shares Held

10.6M

Call Options Held

370K

Put Options Held

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rothschild & CO Asset Management Us Inc., based on Form 13F filings with the SEC.

News

Stay updated on Rothschild & CO Asset Management Us Inc. with notifications on news.

Account

Rothschild & CO Asset Management Us Inc. Revance Therapeutics, Inc. Transaction History